FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine and pharmaceutics, particularly to a pharmaceutical composition containing an effective amount of anti-CD3*CD19 recombinant monoclonal antibody specified in a group containing the antibody SEQ ID No. 1 or the antibody SEQ ID No. 2, as well as phosphate-buffer saline, surfactant and mannitol in the concentration of 1.5-3.0%, as well as to using these compositions for treating B-cell malignancies or B-cell depletion.
EFFECT: group of inventions provides a longer shelf life of the composition.
5 cl, 3 ex, 10 tbl, 6 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODIES AGAINST CD3*CD19 | 2015 |
|
RU2651776C2 |
| METHODS FOR MAKING BISPECIFIC ANTIBODIES AGAINST CD3*CD19 IN FLEXYBODY FORMAT IN MAMMALIAN CELLS | 2014 |
|
RU2577226C2 |
| COMPLEMENTARITY-DETERMINING REGIONS FOR BINDING CD3 AND A BISPECIFIC ANTIGEN-BINDING MOLECULE CONTAINING THEREOF | 2019 |
|
RU2738802C1 |
| BISPECIFIC ASYMMETRIC HETERODIMERS COMPRISING ANTI-CD3 CONSTRUCTS | 2013 |
|
RU2650868C2 |
| NEW TREATMENT OF ACUTE LYMPHOBLASTIC LEUKAEMIA | 2009 |
|
RU2536940C2 |
| HUMANISED CD19 ANTIBODIES AND USING THEM FOR TREATING TRANSPLANTATION-RELATED ONCOLOGICAL AND AUTOIMMUNE DISEASE | 2007 |
|
RU2495882C2 |
| DOSE SCHEDULE FOR ADMINISTERING CD19×CD3 BISPECIFIC ANTIBODY | 2010 |
|
RU2548746C2 |
| CD19 X CD3-SPECIFIC POLYPEPTIDES AND THEIR APPLICATION | 1999 |
|
RU2228202C2 |
| METHOD FOR UPREGULATING ANTIGEN EXPRESSION | 2014 |
|
RU2681953C2 |
| METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY | 2012 |
|
RU2688185C2 |
